121P Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: Final data

ConclusionHDIL2/XRT combined treatment is well tolerated and fairly active in the MM and RCC settings.Clinical trial identificationEudraCT: 2012-001786-32.Legal entity responsible for the studyThe authors.FundingItalian Ministry of Health as part of the “Ricerca Finalizzata 2009 - Direzione Generale della Ricerca Scientifica e Tecnologica” Call for Project Proposals.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research